![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
EG110A is a gene therapy for the treatment which works by silencing the type-C neurons, being developed for Neurogenic Detrusor Overactivity in Spinal Cord Injury patients.
Lead Product(s): EG110A
Therapeutic Area: Neurology Product Name: EG110A
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2024
Details:
EG110A is based on company's unique non-replicative HSV-1 vector platform. It is being evaluated in preclinical studies for the treatment of neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
Lead Product(s): EG110A
Therapeutic Area: Urology Product Name: EG110A
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
The funding will be used to advance company's pipeline, culminating in the Investigational New Drug application filing for the first clinical study of its lead product, EG110A which targets the silencing of type-C sensory neuronsm and is being developed in urology indications.
Lead Product(s): EG110A
Therapeutic Area: Urology Product Name: EG110A
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $20.2 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 13, 2023